Recommendation to reconsider examining cannabis subtypes together due to opposing effects on brain, cognition and behavior

Neuroscience and Biobehavioral Reviews

Volumn 80, Issue , 2017, Pages 156-158

  Rømer Thomsen, Kristine ^a   Callesen, Mette Buhl ^a   Feldstein Ewing, Sarah W ^b  

^a AARHUS UNIVERSITY   (Denmark)

^b OREGON HEALTH AND SCIENCE UNIVERSITY   (United States)

Author keywords

Cannabidiol; Cannabis; Cognition; Delta 9 tetrahydrocannabinol; Learning; Memory; Potency

Indexed keywords

CANNABIDIOL; CANNABIS; TETRAHYDROCANNABINOL; DRONABINOL;

ANTIPSYCHOTIC EFFECT; ANXIETY DISORDER; BEHAVIOR; BRAIN; CANNABIS USE; COGNITION; DRUG ACTIVITY; DRUG EFFECT; DRUG POTENCY; FACIAL EMOTIONAL RECOGNITION IMPAIRMENT; HUMAN; LEARNING DISORDER; MEMORY DISORDER; NOTE; PRIORITY JOURNAL; PSYCHOSIS; SYSTEMATIC REVIEW (TOPIC); TRANQUILIZING ACTIVITY; SCHIZOPHRENIA;

BRAIN; CANNABIDIOL; CANNABIS; COGNITION; DRONABINOL; HUMANS; SCHIZOPHRENIA;

EID: 85020275555     PISSN: 01497634     EISSN: 18737528     Source Type: Journal    
DOI: 10.1016/j.neubiorev.2017.05.025     Document Type: Note

References (28)

1. Bhattacharyya, S., Morrison, P.D., Fusar-Poli, P., Martin-Santos, R., Borgwardt, S., Winton-Brown, T., Nosarti, C., CM, O.C., Seal, M., Allen, P., Mehta, M.A., Stone, J.M., Tunstall, N., Giampietro, V., Kapur, S., Murray, R.M., Zuardi, A.W., Crippa, J.A., Atakan, Z., McGuire, P.K., Opposite effects of delta-9-tetrahydrocannabinol and cannabidiol on human brain function and psychopathology. Neuropsychopharmacology 35 (2010), 764–774.
2. Borgwardt, S.J., Allen, P., Bhattacharyya, S., Fusar-Poli, P., Crippa, J.A., Seal, M.L., Fraccaro, V., Atakan, Z., Martin-Santos, R., O'Carroll, C., Rubia, K., McGuire, P.K., Neural basis of Delta-9-tetrahydrocannabinol and cannabidiol: effects during response inhibition. Biol. Psychiatry 64 (2008), 966–973.
3. Broyd, S.J., van Hell, H.H., Beale, C., Yucel, M., Solowij, N., Acute and chronic effects of cannabinoids on human cognition-a systematic review. Biol. Psychiatry 79 (2016), 557–567.
4. Curran, H.V., Freeman, T.P., Mokrysz, C., Lewis, D.A., Morgan, C.J., Parsons, L.H., Keep off the grass? Cannabis, cognition and addiction. Nat. Rev. Neurosci. 17 (2016), 293–306.
5. D'Souza, D.C., Perry, E., MacDougall, L., Ammerman, Y., Cooper, T., Wu, Y.T., Braley, G., Gueorguieva, R., Krystal, J.H., The psychotomimetic effects of intravenous delta-9-tetrahydrocannabinol in healthy individuals: implications for psychosis. Neuropsychopharmacology 29 (2004), 1558–1572.
6. Das, R.K., Kamboj, S.K., Ramadas, M., Yogan, K., Gupta, V., Redman, E., Curran, H.V., Morgan, C.J., Cannabidiol enhances consolidation of explicit fear extinction in humans. Psychopharmacology (Berl.) 226 (2013), 781–792.
7. Dujourdy, L., Besacier, F., A study of cannabis potency in France over a 25 years period (1992–2016). Forensic Sci. Int. 272 (2017), 72–80.
8. Englund, A., Morrison, P.D., Nottage, J., Hague, D., Kane, F., Bonaccorso, S., Stone, J.M., Reichenberg, A., Brenneisen, R., Holt, D., Feilding, A., Walker, L., Murray, R.M., Kapur, S., Cannabidiol inhibits THC-elicited paranoid symptoms and hippocampal-dependent memory impairment. J. Psychopharmacol. 27 (2013), 19–27.
9. Feldstein Ewing, S.W., Lovejoy, T.I., Choo, E.K., How has legal recreational cannabis affected adolescents in your state? A window of opportunity. Am. J. Public Health 107 (2017), 246–247.
10. Fusar-Poli, P., Crippa, J.A., Bhattacharyya, S., Borgwardt, S.J., Allen, P., Martin-Santos, R., Seal, M., Surguladze, S.A., O'Carrol, C., Atakan, Z., Zuardi, A.W., McGuire, P.K., Distinct effects of {delta}9-tetrahydrocannabinol and cannabidiol on neural activation during emotional processing. Arch. Gen. Psychiatry 66 (2009), 95–105.
11. Hindocha, C., Freeman, T.P., Schafer, G., Gardener, C., Das, R.K., Morgan, C.J., Curran, H.V., Acute effects of delta-9-tetrahydrocannabinol, cannabidiol and their combination on facial emotion recognition: a randomised, double-blind, placebo-controlled study in cannabis users. Eur. Neuropsychopharmacol. 25 (2015), 325–334.
12. Iseger, T.A., Bossong, M.G., A systematic review of the antipsychotic properties of cannabidiol in humans. Schizophr. Res. 162 (2015), 153–161.
13. Jackson, N.J., Isen, J.D., Khoddam, R., Irons, D., Tuvblad, C., Iacono, W.G., McGue, M., Raine, A., Baker, L.A., Impact of adolescent marijuana use on intelligence: results from two longitudinal twin studies. Proc. Natl. Acad. Sci. U. S. A. 113 (2016), E500–508.
14. Laprairie, R.B., Bagher, A.M., Kelly, M.E., Denovan-Wright, E.M., Cannabidiol is a negative allosteric modulator of the cannabinoid CB1 receptor. Br. J. Pharmacol. 172 (2015), 4790–4805.
15. Leweke, F.M., Piomelli, D., Pahlisch, F., Muhl, D., Gerth, C.W., Hoyer, C., Klosterkotter, J., Hellmich, M., Koethe, D., Cannabidiol enhances anandamide signaling and alleviates psychotic symptoms of schizophrenia. Transl. Psychiatry, 2, 2012, e94.
16. Meier, M.H., Caspi, A., Ambler, A., Harrington, H., Houts, R., Keefe, R.S., McDonald, K., Ward, A., Poulton, R., Moffitt, T.E., Persistent cannabis users show neuropsychological decline from childhood to midlife. Proc. Natl. Acad. Sci. U. S. A. 109 (2012), E2657–2664.
17. Mokrysz, C., Landy, R., Gage, S.H., Munafo, M.R., Roiser, J.P., Curran, H.V., Are IQ and educational outcomes in teenagers related to their cannabis use: a prospective cohort study. J. Psychopharmacol. 30 (2016), 159–168.
18. Morgan, C.J., Gardener, C., Schafer, G., Swan, S., Demarchi, C., Freeman, T.P., Warrington, P., Rupasinghe, I., Ramoutar, A., Tan, N., Wingham, G., Lewis, S., Curran, H.V., Sub-chronic impact of cannabinoids in street cannabis on cognition, psychotic-like symptoms and psychological well-being. Psychol. Med. 42 (2012), 391–400.
19. Morrison, P.D., Zois, V., McKeown, D.A., Lee, T.D., Holt, D.W., Powell, J.F., Kapur, S., Murray, R.M., The acute effects of synthetic intravenous Delta9-tetrahydrocannabinol on psychosis, mood and cognitive functioning. Psychol. Med. 39 (2009), 1607–1616.
20. National Academies of Sciences, E., and Medicine, The Health Effects of Cannabis and Cannabinoids: The Current State of Evidence and Recommendations for Research. 2017 Washington, DC.
21. Niesink, R.J., Rigter, S., Koeter, M.W., Brunt, T.M., Potency trends of Delta9-tetrahydrocannabinol, cannabidiol and cannabinol in cannabis in the Netherlands: 2005-15. Addiction 110 (2015), 1941–1950.
22. Osborne, A.L., Solowij, N., Weston-Green, K., A systematic review of the effect of cannabidiol on cognitive function: relevance to schizophrenia. Neurosci. Biobehav. Rev. 72 (2017), 310–324.
23. Pertwee, R.G., The diverse CB1 and CB2 receptor pharmacology of three plant cannabinoids: delta9-tetrahydrocannabinol, cannabidiol and delta9-tetrahydrocannabivarin. Br. J. Pharmacol. 153 (2008), 199–215.
24. Winton-Brown, T.T., Allen, P., Bhattacharyya, S., Borgwardt, S.J., Fusar-Poli, P., Crippa, J.A., Seal, M.L., Martin-Santos, R., Ffytche, D., Zuardi, A.W., Atakan, Z., McGuire, P.K., Modulation of auditory and visual processing by delta-9-tetrahydrocannabinol and cannabidiol: an FMRI study. Neuropsychopharmacology 36 (2011), 1340–1348.
25. Zamengo, L., Frison, G., Bettin, C., Sciarrone, R., Cannabis potency in the Venice area (Italy): update 2013. Drug Test Anal. 7 (2015), 255–258.
26. Zuardi, A.W., Morais, S.L., Guimaraes, F.S., Mechoulam, R., Antipsychotic effect of cannabidiol. J. Clin. Psychiatry 56 (1995), 485–486.
27. Zuardi, A.W., Hallak, J.E., Dursun, S.M., Morais, S.L., Sanches, R.F., Musty, R.E., Crippa, J.A., Cannabidiol monotherapy for treatment-resistant schizophrenia. J. Psychopharmacol. 20 (2006), 683–686.
28. Zuardi, A.W., Crippa, J.A., Hallak, J.E., Pinto, J.P., Chagas, M.H., Rodrigues, G.G., Dursun, S.M., Tumas, V., Cannabidiol for the treatment of psychosis in Parkinson's disease. J. Psychopharmacol. 23 (2009), 979–983.